UNSPSC 51113401: Aceglatone

This classification denotes a glucuronidase inhibitor with the molecular formula C10H10O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 347Q3OOJ13, chemically known as 2,5-di-o-acetyl-d-glucosaccharo-1,4:6,3-dilactone but more generally known as aceglatone, which bears US NIH Compound Identifier 1980. European Medicines Agency schedules Aceglatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05207MIG.

UNSPSC 51113401 Aceglatone, a Commodity code, describes pharmaceutical active pharmaceutical ingredients and finished-dose medications that state and local governments procure through health and human services agencies for pharmacy benefit programs, Medicaid formularies, and direct-to-manufacturer prescription fulfillment initiatives. The Texas Health and Human Services Commission (HHS) issued a Request for Information (RFI) No. HHS0017013 in April 2026 seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program—a sourcing model that bypasses traditional pharmacy benefit managers, group purchasing organizations, and wholesalers in favor of direct state-to-manufacturer relationships. State health agencies are the primary issuing bodies under this code, procuring pharmaceutical products and related supply-chain services to optimize prescription fulfillment costs and improve access to medications for state employees, retirees, and Medicaid beneficiaries.

The recent activity shows geographic concentration in Texas, where the HHS Commission's April 2026 RFI sought information on vendors' capacity to negotiate net-pricing contracts, implement value-based or outcomes-based pharmaceutical agreements, and fulfill volume requirements through direct manufacturer relationships without traditional intermediary channels. The RFI targeted vendors with prior experience entering direct contracts with self-insured employers and government health plans within the preceding two years. No formal award value, budget allocation, or response evaluation criteria were disclosed in this preliminary information-gathering phase; the RFI was designed to inform subsequent formal procurement strategy and detailed specifications before issuing a binding Request for Proposal. State and local pharmaceutical procurement under this code remains limited in visible recent opportunities beyond Texas HHS's exploratory activity.